Pietro Achilli1, Paolo De Martini2, Marco Ceresoli3, Giulio M Mari4, Andrea Costanzi4, Dario Maggioni4, Raffaele Pugliese2, Giovanni Ferrari2. 1. Università degli studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Sforza, Milano, Italy. 2. Dipartimento di Chirurgia Oncologica Mininvasiva, Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore, Milano (MI), Italy. 3. Università degli Studi di Milano-Bicocca, Via Cadore, Monza (MI), Italy. 4. U.O.C. Chirurgia Generale, Ospedale di Desio, Via Mazzini 1, Desio, Italy.
Abstract
BACKGROUND: To verify the prognostic value of the pathologic and radiological tumor response after neoadjuvant chemotherapy in the treatment of locally advanced gastric adenocarcinoma. METHODS: A total of 67 patients with locally advanced gastric cancer (clinical ≥ T2 or nodal disease and without evidence of distant metastases) underwent perioperative chemotherapy (ECF or ECX regimen) from December 2009 through June 2015 in two surgical units. Histopathological and radiological response to chemotherapy were evaluated by using tumor regression grade (TRG) (Becker's criteria) and volume change assessed by CT. RESULTS: Fifty-one (86%) patients completed all chemotherapy scheduled cycles successfully and surgery was curative (R0) in 64 (97%) subjects. The histopathological analysis showed 19 (29%) specimens with TRG1 (less than 10% of vital tumor left) and 25 (37%) patients had partial or complete response (CR) assessed by CT scan. Median disease free survival (DFS) and overall survival (OS) were 25.70 months (range, 14.52-36.80 months) and 36.60 months (range, 24.3-52.9 months), respectively. The median follow up was 27 months (range, 5.00-68.00 months). Radiological response and TRG were found to be a prognostic factor for OS and DFS, while tumor histology was not significantly related to survival. CONCLUSIONS: Both radiological response and TRG have been shown as promising survival markers in patients treated with perioperative chemotherapy for locally advanced gastric cancer. Other predictive markers of response to chemotherapy are strongly required.
BACKGROUND: To verify the prognostic value of the pathologic and radiological tumor response after neoadjuvant chemotherapy in the treatment of locally advanced gastric adenocarcinoma. METHODS: A total of 67 patients with locally advanced gastric cancer (clinical ≥ T2 or nodal disease and without evidence of distant metastases) underwent perioperative chemotherapy (ECF or ECX regimen) from December 2009 through June 2015 in two surgical units. Histopathological and radiological response to chemotherapy were evaluated by using tumor regression grade (TRG) (Becker's criteria) and volume change assessed by CT. RESULTS: Fifty-one (86%) patients completed all chemotherapy scheduled cycles successfully and surgery was curative (R0) in 64 (97%) subjects. The histopathological analysis showed 19 (29%) specimens with TRG1 (less than 10% of vital tumor left) and 25 (37%) patients had partial or complete response (CR) assessed by CT scan. Median disease free survival (DFS) and overall survival (OS) were 25.70 months (range, 14.52-36.80 months) and 36.60 months (range, 24.3-52.9 months), respectively. The median follow up was 27 months (range, 5.00-68.00 months). Radiological response and TRG were found to be a prognostic factor for OS and DFS, while tumor histology was not significantly related to survival. CONCLUSIONS: Both radiological response and TRG have been shown as promising survival markers in patients treated with perioperative chemotherapy for locally advanced gastric cancer. Other predictive markers of response to chemotherapy are strongly required.
Authors: Sook Ryun Park; Jong Seok Lee; Chan Gyoo Kim; Hark Kyun Kim; Myeong-Cherl Kook; Young-Woo Kim; Keun Won Ryu; Jun Ho Lee; Jae-Moon Bae; Il Ju Choi Journal: Cancer Date: 2008-06 Impact factor: 6.860
Authors: S Blank; A Stange; L Sisic; W Roth; L Grenacher; F Sterzing; M Burian; D Jäger; M Büchler; K Ott Journal: Langenbecks Arch Surg Date: 2012-12-07 Impact factor: 3.445
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: R Molina; A Lamarca; B Martínez-Amores; A Gutiérrez; A Blázquez; A López; J Granell; M Álvarez-Mon Journal: Eur J Surg Oncol Date: 2013-06-05 Impact factor: 4.424
Authors: Fernando Mingol; Javier Gallego; Albina Orduña; Amparo Martinez-Blasco; Javier Sola-Vera; Pedro Moya; Miguel Angel Morcillo; Juan Antonio Ruiz; Rafael Calpena; Francisco-Javier Lacueva Journal: BMC Surg Date: 2015-05-22 Impact factor: 2.102
Authors: T Schmidt; L Sicic; S Blank; K Becker; W Weichert; T Bruckner; T Parakonthun; R Langer; M W Büchler; J-R Siewert; F Lordick; K Ott Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640
Authors: Beate Rau; Andreas Brandl; Peter Thuss-Patience; Fabian Bergner; Wieland Raue; Alexander Arnold; David Horst; Johann Pratschke; Matthias Biebl Journal: Gastric Cancer Date: 2019-05-07 Impact factor: 7.370